Date:7/28/2011

rate movements had a negative effect of 6.4 percentage points, of which more than 70% was due to the weakening of the U.S. dollar versus the Euro. Various currencies from Emerging Markets (notably the Venezuelan Bolivar, Chinese Yuan and the Turkish Lira) also had an unfavorable impact. At constant exchange rates, and including changes in structure (primarily the consolidation of Genzyme from April 1st), net sales increased by 6.9%.

Net sales in the first half of 2011 were euro 16,128 million, a decrease of 0.5% on a reported basis. Exchange rate movements had an unfavorable effect of 1.5 percentage points. The depreciation of the U.S. dollar, and the Venezuelan Bolivar against the Euro was partially offset by the favorable effect of the Japanese Yen and the Australian dollar. At constant exchange rates, and after taking into account changes in structure (primarily the consolidation of Genzyme from April 1st), net sales increased by 1.0%.

Growth Platforms (see Appendix 4)The Group's growth platforms grew by 9.5% and including Genzyme accounted for 65.2% of total consolidated sales in the second quarter of 2011, which is up from 54.9% in the second quarter of 2010. In the first half of 2011, the growth platforms and Genzyme comprised 62.3% of total consolidated sales compared with 54.4% for the first half of 2010. Over the period, growth platforms grew by 12.3% excluding A/H1N1 vaccines sales.

PharmaceuticalsSecond-quarter net sales for the Pharmaceuticals business were euro 7,147 million (up 7.7%), which reflects the positive impact (euro 796 million) from the consolidation of Genzyme from April 1st, 2011 as well as generic competition to Lovenox®, Ambien®CR and Taxotere® in the U.S., Plavix® and Taxotere® in the EU and the impact of U.S. healthcare reform and EU austerity measures. First-half 2011 net sales increased 3.3% to euro 13,730 million.

Flagship Prod
'/>"/>

SOURCE Sanofi Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
Related medicine technology :

1. New Senior Executives Appointed at Sanofi:
2. VR Business Sales, Mergers & Acquisitions Charlotte Completes Sale of Penrod Medical Equipment
3. Global Medical Devices Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Marketing Spend and Sales Strategies
4. TPI Ships Macrolide API Samples for International Sales Standard Testing
5. Unilife Starts Unifill Syringe Sales to Another Pharmaceutical Customer
6. Burlington Medical Supplies Reorganizes Sales and Marketing Operations
7. HASCO Medical Inc. Names Mike Dumais the Vice President of Sales for Southern Medical and Mobility
8. GlaxoSmithKline Implements Next Phase of New Incentive Compensation Program for U.S. Sales Representatives
9. With Launch of New ActiveHome Monitoring System, ActiveCare Announces New Head of Sales and Marketing
10. TPI Signs Macrolide API International Sales and Marketing Agreement
11. CellerateRX TV Commercials Begin Airing on Fox News Network via Geraldo at Large and Fox News Sunday Programs, Expanding the Direct-To-Consumer Sales Program